Piramal Pharma Limited, offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the- counter products. In addition, one of PPL’s associate companies, AbbVie Therapeutics India Private Limited is a JV with AbbVie Inc. and has emerged as one of the market leaders in the ophthalmology therapy area. Further, PPL has a minority investment in Yapan Bio Private Limited. In October 2020, PPL received a 20% strategic growth investment from the Carlyle Group.

Piramal Pharma Limited is a part of the Piramal Group, a global business conglomerate with diverse interests in pharma, financial services, and real estate. The Group has offices in over 30 countries and a global brand presence in more than 100 markets, and operates with over 10,000 people worldwide from 21 diverse nationalities.

VISION : At Piramal Pharma Limited, we are dedicated to creating a positive impact on the well-being of our patients and consumers through the delivery of exceptional products and services. We strive to serve not only our patients and customers but also our broader community, employees, partners, stakeholders, and the environment. Our commitment is reflected in the embodiment of our values, evident in both personal and corporate actions, decisions, and conduct in our daily operations.